We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Titanium Sprayed Fusion Device Facilitates Osseointegration

By HospiMedica International staff writers
Posted on 01 Oct 2013
A new fusion device has been specifically designed for situations where polyether ether ketone (PEEK) alone may not provide the best setting for fusion.

The TyPEEK interbody fusion devices are a novel solution for fusion procedures that combines the properties of Titanium plasma spray with the modulus of PEEK. More...
The proprietary highly roughened surface can provide a more favorable environment for early stability, and the potential to promote intimate osseointegration between bone and implant. The devices include configurations for anterior cervical, anterior lumbar, posterior lumbar, oblique lumbar, transforaminal lumbar, and direct lateral interbody fusions.

Benefits of the fusion devices include anatomical endplate contact, a large graft window, a PEEK-Optima Core, and simple instrumentation for placement with a retractor system. Configurations include multiple height options, multiple lordotic angels, and multiple length and width options. The TyPEEK interbody fusion devices are products of Tyber Medical (Morristown, NJ, USA), and have received the European Community CE marking of approval.

“The Tyber Medical Interbody portfolio offers our customers immediate access to a regulatory approved system, ranging from economical nonsterile PEEK to our highly differentiated proprietary Titanium Plasma Sprayed TyPEEK,” said Jeff Tyber, CEO of Tyber Medical. “We are excited to give the versatility and customization of choice back to our customer, with the option to purchase a full system solution or an a la carte selection; trays, instrument, or implant.”

Related Links:
Tyber Medical



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.